XML 74 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation, Restricted Stock and Stock Options (Tables)
9 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of stock based compensation expenses
  

Nine months ended

   Fiscal year ended 
   December 31,
2021
   March 31,
2021
 
Research and development expenses  $384   $2,444 
Selling, general and administrative expenses   8,318    11,987 
Total stock-based compensation  $8,702   $14,431 

 

Schedule of restricted stock awards
   Number of Shares  

Weighted Average
Grant-Date

Fair Value

 
Unvested at March 31, 2021   1,061,905   $4.50 
Granted   1,200,000   $1.33 
Vested   (322,222)  $1.24 
Unvested at December 31, 2021   1,939,683   $3.08 

 

   Number of Shares  

Weighted Average
Grant-Date

Fair Value

 
Unvested at March 31, 2021   777,778   $           5.12 
Vested   (66,666)  $5.12 
Canceled   (711,112)  $5.12 
Unvested at December 31, 2021   
-
   $
-  
 

 

Schedule of of stock options granted
   Nine months
ended
   Fiscal year
ended
 
   December 31,
2021
   March 31,
2021
 
Dividend yield   0%   0%
Expected price volatility   50% - 103%   50%
Risk free interest rate   0.35% - 1.33%   0.16% - 0.94%
Expected term   3-7 years    1-7 years 

 

Schedule of stock options
   Shares Underlying
Options
   Weighted Average
Exercise Price
   Weighted Average
Remaining
Contractual
Term (Years)
   Aggregate Intrinsic
Value
 
Outstanding at March 31, 2021   10,928,607*  $2.73    8.2   $17,524 
Granted   1,442,204   $3.53    9.8      
Exercised   (419,000)  $0.51    -      
Canceled   (816,379)  $3.88    -      
Outstanding at December 31, 2021   11,135,432   $2.85    7.6   $13,031 
                     
Exercisable at December 31, 2021   9,850,155   $2.75    7.4   $12,402 

 

Schedule of warrant activity
   Shares Underlying
Warrants
   Weighted Average
Exercise Price
   Weighted Average
Remaining
Contractual
Term (Years)
   Aggregate Intrinsic
Value
 
                 
Outstanding at March 31, 2021   3,883,083   $2.49    4.6   $7,763 
Issued   775,724   $3.94    4.8      
Canceled   (133,630)  $5.63    -      
Outstanding at December 31, 2021   4,525,177   $2.65    4.0   $7,088 
                     
Exercisable at December 31, 2021   3,468,422   $1.95    3.8   $6,751 

 

Schedule of estimated the fair value of the warrants
   Nine months ended
December 31,
2021
   Fiscal year ended
March 31,
2021
 
         
Expected price volatility   50% - 103%   50.0%
Risk free interest rate   0.81% - 1.2%   0.4% - 2.4%
Expected term   5 years    5 years